search
Back to results

Radiofrequency Splanchnic Denervation Versus Retrocrural Neurolytic Celiac Block for Pancreatic Cancer Pain

Primary Purpose

Chronic Pain

Status
Unknown status
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
radiofrequency splanchnic denervation
retrocrural celiac denervation
Sponsored by
Assiut University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Pain

Eligibility Criteria

16 Years - 90 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • patients with abdominal pain due to cancer pancreas

Exclusion Criteria:

  • coagulopathy
  • infection at site of the procedure

Sites / Locations

  • DiabRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

radiofrequency splanchnic denervation

retrocrural celiac denervation

Arm Description

Outcomes

Primary Outcome Measures

the percentage of patients that gain more than 50% reduction of their pain on VAS pain score
VAS pain scale is a tool for measurement of pain intensity scored from 0 to 10 in which 0 + no pain and 10 + the worst pain immaginable

Secondary Outcome Measures

Full Information

First Posted
March 20, 2019
Last Updated
July 3, 2019
Sponsor
Assiut University
search

1. Study Identification

Unique Protocol Identification Number
NCT03886298
Brief Title
Radiofrequency Splanchnic Denervation Versus Retrocrural Neurolytic Celiac Block for Pancreatic Cancer Pain
Official Title
For Patients With Pancreatic Cancer Pain, Does Radiofrequency Splanchnic Denervation Isprovide a Similar Analgesia as Neurolytic Celiac Block
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Unknown status
Study Start Date
April 10, 2019 (Actual)
Primary Completion Date
April 10, 2020 (Anticipated)
Study Completion Date
June 10, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Assiut University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The investigators will evaluate the analgesic efficacy of radiofrequency splanchnic nerve denervation versus neurolytic retrocrural celiac denervation for patients with abdominal pain due to cancer pancreas

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
radiofrequency splanchnic denervation
Arm Type
Experimental
Arm Title
retrocrural celiac denervation
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
radiofrequency splanchnic denervation
Intervention Description
the authors will denervate the splanchnic nerves via radiofrequency
Intervention Type
Procedure
Intervention Name(s)
retrocrural celiac denervation
Intervention Description
the authors will denervate the splanchnic nerves in the retrocrural space via injection of alcohol
Primary Outcome Measure Information:
Title
the percentage of patients that gain more than 50% reduction of their pain on VAS pain score
Description
VAS pain scale is a tool for measurement of pain intensity scored from 0 to 10 in which 0 + no pain and 10 + the worst pain immaginable
Time Frame
6 months postoperatively

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patients with abdominal pain due to cancer pancreas Exclusion Criteria: coagulopathy infection at site of the procedure
Facility Information:
Facility Name
Diab
City
Assiut
State/Province
Assuit
ZIP/Postal Code
71515
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Diab Hetta, MD
Phone
+201091090009
Email
diabgetta25@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Radiofrequency Splanchnic Denervation Versus Retrocrural Neurolytic Celiac Block for Pancreatic Cancer Pain

We'll reach out to this number within 24 hrs